• OPEN AN ACCOUNT
Indian Indices
Nifty
24,750.70 -82.90
(-0.33%)
Sensex
81,451.01 -182.01
( -0.22%)
Bank Nifty
55,749.70 203.65
( 0.37%)
Nifty IT
37,321.75 -432.40
( -1.15%)
Global Indices
Nasdaq
42,280.67 43.94
(0.10%)
Dow Jones
5,931.28 -1.89
(-0.03%)
Hang Seng
38,097.61 -335.37
(-0.87%)
Nikkei 225
8,772.38 55.93
(0.64%)
Forex
USD-INR
85.50 0.07
(0.09%)
EUR-INR
97.01 0.42
(0.44%)
GBP-INR
115.18 0.03
(0.03%)
JPY-INR
0.59 0.00
(0.53%)

EQUITY - MARKET SCREENER

Muller & Phipps (India) Ltd
Industry :  Trading
BSE Code
ISIN Demat
Book Value()
501477
INE003F01015
-23.8352
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
N.A
0
14
EPS(TTM)
Face Value()
Div & Yield %
0
10
0
 

Venus Remedies spurts after Q4 PAT climbs 100% YoY to Rs 21 cr
May 27,2025
However, revenue from operations decreased marginally to Rs 194.97 crore in Q4 FY25, as against Rs 195.16 crore posted in the corresponding quarter of the previous year.

Profit before tax surged 77.57% to Rs 31.04 crore in Q4 FY25, compared to Rs 17.48 crore in Q4 FY24.

Total expenses slipped 6.01% YoY to Rs 170.69 crore in Q4 FY25. The cost of materials consumed was Rs 104.21 crore (up 23.80% YoY), while employee benefits expenses stood at Rs 21.16 crore (up 7.35% YoY) during the March 2025 quarter.

During Q4 FY25, EBITDA stood at Rs 35.77 crore, up 52.92% from Rs 23.39 crore posted in the corresponding quarter last year.

On a full-year basis, the company's consolidated net profit surged 59.07% to Rs 45.32 crore on a 7.72% jump in revenue from operations to Rs 647.89 crore in FY25 over FY24.

Venus Remedies is an Indian research-driven pharmaceutical company dedicated to developing innovative solutions to improve patient outcomes.